Unmet medical needs require sustainable and innovative solutions Unmet medical needs (UMN), especially in areas that are commercially unappealing, may be addressed by drug repurposing, which also has the potential to reduce both development time & cost.
AF
Anticancer Fund
NGO · Belgium · EU Transparency Register 404359320127-95
5
positions filed
in the 665 files tracked
3
legislative files
of 665 tracked
3
with a full position paper
attached to a submission
Counts here are a floor, never a total: they cover the 665 consultation files tracked so far (57,774 submissions, mostly 2021–26), so an organization's real filing history is larger, not smaller.
Who they are
Among the 1106 non-governmental organisations on this site, they rank #379 by legislative files engaged, a count of participation, not a measure of influence.
1.6
declared lobbying FTE
self-declared
–
declared costs / yr (floor)
2
EP accreditations
as declared to the register
2015
in the register since
Declares membership of
- https://www.icrpartnership.org/
- https://www.europeancancer.org/
- https://consilium-scientific.org/ (Advisory Board)
Self-declared to the EU Transparency Register (snapshot 14 Oct 2026).
- Register category
- Non-governmental organisations
- Head office
- Meise, Belgium
Self-declared to the EU Transparency Register (snapshot 14 Oct 2026); cost bands are floors, not audited totals. Reused under Commission Decision 2011/833/EU.
Track Anticancer in PolicySpeak: request access →
Work at Anticancer Fund? so we know who speaks for it.
Their record over time
Anticancer Fund filed 5 positions between 5 Jan 2021 and 5 Aug 2026, across 3 of the 665 legislative files tracked here, attaching a full position paper 3 times.
2021 · 2 filed2023 · 1 filed2026 · 2 filed
What they argued
The European Commission states its intention for its Pharmaceutical Strategy for Europe to be ‘patient-centred’. However, it is crucial that the concept of ‘patient value’ is integrated in the pharmaceutical legislation.
Anticancer Fund welcomes the proposed Biotech Act and particularly the need to simplify and streamline the Clinical Trials Regulation. Being strong supporters of resolution WHA75.8 (2022) on strengthening clinical trials to provide high-quality evidence on health interventions and to improve research quality and coordination, we encourage the consideration of WHOs Global Action Plan for clinical trial ecosystem…
Anticancer Fund welcomes the proposed Biotech Act and particularly the need to simplify and streamline the Clinical Trials Regulation. Being strong supporters of resolution WHA75.8 (2022) on strengthening clinical trials to provide high-quality evidence on health interventions and to improve research quality and coordination, we encourage the consideration of WHOs Global Action Plan for clinical trial ecosystem…
The Anticancer fund applauds the awareness of the commission that in oncology common cancers are split into many subsets based on biomarkers, leading to unnecessary multiplication of rare diseases. Therefore, we support the idea that it will no longer be possible to obtain orphan designation for subsets of common diseases.
Looking for an argument rather than an organization? Search every submission for a phrase and see everyone who used it.
Put Anticancer Fund next to another organization. Same files, same register facts, side by side. Compare →
Turns up on the same files
Organizations that also filed on at least two of the same consultations. A shared interest in the same dossiers, not evidence of coordination, and we do not suggest any.
Showing 5 of 96.
Is this your organization?
Everything on this page comes from Anticancer Fund’s own submissions to the European Commission. We have added nothing and interpreted nothing. If something is wrong or out of date, email info@policyspeak.com and we will correct it. If you are an individual named in a record, our privacy policy sets out your rights to correction, objection and removal.
Quotes are verbatim from submissions published by the European Commission, trimmed to their opening passage and never summarized by a model. Organizations only, never individuals. Reused under Commission Decision 2011/833/EU; the European Commission is not liable for this reuse.